Drugs online research references
Metabolism. 2003 Oct;52(10):1240-5.
Doxazosin, an alpha-1 antagonist, prevents further progression of the advanced atherosclerotic lesion in hypercholesterolemic hamsters.
Wilson TA, Foxall TL, Nicolosi RJ.
Center for Health and Disease Research, Division of Nutrition and Metabolic Disorders, Univeristy of Massachusetts Lowell, Lowell, MA 01854, USA.
The aim of this study was to examine the effect of doxazosin (DOX) on the further progression and regression of the advanced atherosclerotic lesion in the hypercholesterolemic hamster. Thirty-six, male F(1)B Golden Syrian hamsters, 10 weeks of age, were divided into 3 groups of 12 and fed a nonpurified hypercholesterolemic diet (HCD) containing 10% coconut oil and 0.1% cholesterol (wt/wt) for 9 months (HCD 9). One group of hamsters was euthanized at 9 months and their aortas were collected, fixed, and stored until analysis. The remaining hamsters were either maintained on the HCD for an additional 6 months (HCD 15) or fed the HCD plus 20 mg/kg/d DOX for the 6 months. At the end of the study (15 months), the DOX-treated hamsters had significantly lower plasma total cholesterol (TC) (-68%), low-density lipoprotein-cholesterol (LDL-C) (-73%), and triglycerides (TG) (-74%) compared with the HCD 15. The lumenal narrowing and intimal thickening atherosclerotic lesions were significantly less in the DOX-treated hamsters compared with the HCD 15 (-66% and -70%, respectively). These data suggest that DOX treatment prevents further progression of the advanced atherosclerotic lesion possibly by lowering plasma TC, LDL-C, and TG in hypercholesterolemic hamsters.
online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=14564673&dopt=Abstract
J Formos Med Assoc. 2003 Aug;102(8):551-5.
Effectiveness of alpha1-adrenergic blockers in boys with low urinary flow rate and urinary incontinence.
Yang SS, Wang CC, Chen YT.
Department of Urology, En Chu Kong Hospital, Medical College of National Taiwan University, Taipei.
BACKGROUND AND PURPOSE: Although alpha blockers have been shown to be effective in treating various types of neuropathic voiding dysfunction in children, the effectiveness of alpha(1) blockers in treating neurologically intact children with voiding dysfunction remains unclear. We investigated the effectiveness of treatment with alpha(1)-adrenergic blockade in boys with low uroflow rate and urinary incontinence. METHODS: The alpha(1) blocker doxazosin (0.5 to 1.0 mg daily) was administered to 16 boys (mean age, 8.9 +/- 3.4 years) with maximum uroflow rate (Qmax) < 15 mL/s and urinary incontinence. Uroflowmetry and postvoid residual volumes were checked before and 4 weeks after doxazosin treatment. After discontinuation of doxazosin for 2 weeks, videourodynamics and cystoscopy were done in 12 of the 16 boys. Improvement of uroflow was arbitrarily defined as an increase of Qmax >/= 2.5 mL/s. Complete improvement of incontinence was defined as > 90% and partial improvement as 50 to 90% reduction of incontinence episodes. Successful treatment was defined as improvement in uroflow and partial or complete improvement of urinary incontinence. Blood pressure, first-dose phenomenon, and adverse effects were monitored at each visit. RESULTS: Mean medication and follow-up periods were 24.5 weeks and 33.1 weeks, respectively. Improvement of uroflow was noted in 10 patients (63%). Qmax increased from 12.3 +/- 1.3 mL/s to 16.3 +/- 4.1 mL/s (p = 0.001). Complete and partial improvement of incontinence was noted in 7 and 3 patients, respectively. The mean number of wet nights per week decreased from 4.9 +/- 2.3 to 2.2 +/- 2.5 (p < 0.001). Successful treatment was noted in 8 boys (50%), including 3 of 5 boys with primary bladder neck obstruction, 3 of 4 boys with dysfunctional voiding, and 2 of 4 boys with neuropathic voiding dysfunction of unclassified etiology. There were no significant adverse effects. Decreases of systolic and diastolic blood pressure were negligible. CONCLUSION: alpha(1) Blockade is effective in the treatment of boys with low uroflow rate and incontinence.
online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=14569320&dopt=Abstract
Am J Hypertens. 1992 Nov;5(11):827-31.
Glucose, insulin, and lipid metabolism in doxazosin-treated patients with hypertension.
Shieh SM, Sheu WH, Shen DC, Fuh MM, Chen YD, Reaven GM.
Department of Medicine, Stanford University School of Medicine, Palo Alto, California.
The metabolic changes associated with doxazosin treatment of hypertension were evaluated in ten patients with mild hypertension (mean +/- SEM = 150 +/- 3/100 +/- 1 mm Hg) and a plasma triglyceride (TG) concentration > 1.50 mmol/L. The blood pressure was lower after 4 to 6 months of doxazosin treatment (mean +/- SEM = 134 +/- 4/87 +/- 1 mm Hg), which was also associated with a significantly lower plasma insulin response to a 75 g oral glucose load, and lower plasma TG and cholesterol concentrations. In addition, insulin-mediated glucose uptake was significantly greater after doxazosin treatment. These data suggest that doxazosin treatment of patients with mild hypertension is associated with changes in insulin and lipid metabolism that should decrease the risk of coronary heart disease.
online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1457085&dopt=Abstract
online pharmacies ||
Hair Million herbal formula for hair loss and hair growth ||
Amoxicillin ||
Tramadol ||
Paxil ||
Rx Drugs USA, Prescription Drugs Online Pharmacy ||
Zithromax ||
online pharmacy ||
Antibiotics and prescription medications online literature ||
Antibiotics